Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.

The WGND membership rests with individuals, not institutions. Thus, the WGND has no "lead agency" and is not dominated by any institution or group of institutions. Members represent the private and public sectors and come from diverse geographical locations.

Apply Now Learn More View Core Group

Current Members


Name Organization Countrysort descending
Hugo Cesar Gramajo Instituto de Biologia Molecular y Celular de Rosario Argentina
Ahmadul Khan Ahmadul Hasan Khan Bangladesh
Koen Andries Janssen Belgium
Anil Koul Johnson and Johnson Belgium
Marcio Dias University of Sao Paulo Brazil
Fernando Pavan Sao Paulo State University, UNESP, Brazil Brazil
Valerie Flore Donkeng Donfack Pasteur Center in Cameroon Cameroon
Renaud Boulanger McGill University Canada
Yossef Av-Gay University of British Columbia Canada
Doug Lowrie Fudan University's Shanghai Public Health Clinical Center China
Xuelian Zhang Fudan University China
Martin Dolezal Charles University in Prague, Faculty of Pharmacy in Hradec Kralove Czech Republic
Teto Fondacaro Mamona Programme National de Lutte Contre la Tuberculose Democratic Republic Of Congo (Zaire)
Tarek Aboul-Fadl Medicinal Chemistry, Assiut University Egypt
Alexandra Carreau Sanofi-Adventis R&D France
Brigitte Demers Sanofi France
Jacques Grosset Scientist France
Yadav Prasad Joshi Biodyss and Journal Infection in Developing Countries France
Didier Leboulleux Sanofi France
Nicolas Willand Institut Pasteur Lille France
Florence Bordon-Pallier Sanofi France
Isabelle Cieren-Puiseux Sanofi France
Nelly Solomonia National Center for Tuberculosis and Lung Diseases Georgia
Tamari Trapaidze Welfare Foundation Georgia
Nino Lomtadze National Center for Tuberculosis and Lung Diseases Georgia
Norbert Heinrich Universtiy of Munich / PanACEA Germany
Michael Hoelscher Ludwig-Maximilians-University Germany
Nii Nortey Hanson-Nortey Ghana Health Service Ghana
Kobina Bosumtwi Dadzie Wiljok Childaid and Health Organization Ghana
Shekhar Mande National Centre for Cell Science India
Ravishankar Ramachandran CSIR-Central Drug Research Institute, Lucknow, India India
Rajender Kamboj Lupin Limited India
Kampasati Satyanarayana Yuvabharath Society India
P. R. Narayanan Tuberculosis Research Centre, Chennai (retired) India
Tanjore Balganesh CSIR-OSDD India
Khadar Bhatcha PSG College of Pharmacy India
Shreemanta Parida Clinical Scientist India
KR John SRM Medical College India
Sandeep Saluja No affiliation India
Prasad Pasam Shar Technologies Group India
Avishek Anant Novartis India
Sidharth Chopra Central Drug Research Institute, Lucknow India
Samir Roy Government Medical College, Bhavnagar India
Dhanji Rajani Microcare Laboratory India
Kanury Rao International Centre for Genetic Engineering & Biotechnology-New Delhi India
Ronan O'Toole Trinity College Dublin Ireland
Oren Zimhony Kaplan Medical Center, The School of Medicine Hebrew University Israel
Daniela Jabes NeED Parma Italy
Dario Scaramuzzi R-Evolution Group EEIG Italy
Masaji Okada Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center Japan
Tado Shimao Japan Anti-Tuberculosis Association (JATA) Research Institute of TB Japan
Noroi Doi Japan Anti-Tuberculosis Association (JATA) Research Institute of TB Japan
Hiromu Kawakubo Asahi Kasei Chemicals Corporation Japan
Steve Wandiga KEMRI/CDC Kenya
Benson Muriuki Center for the Empowerment Of The Local Herbalist-Celoh Kenya Kenya
Dorothy Odhiambo International Community of Women Living with HIV in Kenya ( ICW-K) Kenya
Nelson Otwoma Positive Familes Network (+FN) Kenya
Alick Chimpimo Makiyi Grassroots Movement for Health and Development (GMHD) Malawi
Rogelio Hernandez Pando National Institute of Medical Sciences and Nutrition, Mexico Mexico
Htay Lwin National TB Program, Myanmar Myanmar (Burma)
Astrid Van der Sar VU University Medical Center Netherlands
Daniel Zollinger QareFree Netherlands
Martin Johan Boeree PanACEA Consortium and the Radboud University Nijmegen Medical Centre Netherlands
Jurriaan de Steenwinkel Erasmus MC Netherlands
Kolawole Ekanoye Advocates for Health and Development Initiative Nigeria
Mohammad Hassan Mashori Fundamental Human Rights & Rural Development Association (FHRRDA) Pakistan
Muhammad Farooq Government of Pakistan Pakistan
Asghar Arif TB Association Charsadda Pak Pakistan
Basharat Khan National TB Control Programme Pakistan
Zahoor Ahmed National TB Control Programme Pakistan
Roberto Salvino No affiliation Philippines
Sergey Koren JSC Pharmasyntez Russia
Aboubacar Sidiki Daffe Université Cheikh Anta DIOP Senegal
Christian Lienhardt World Health Organization (WHO) Senegal
Thomas Dick National University of Singapore Singapore
Manjunatha Ujjini Novartis Institute for Tropical Diseases Singapore
Josef Jampilek Comenius University Slovakia
Abdifetah Ibrahim Omer National TB Programme Somalia Somalia
Bernard Fourie University of Pretoria South Africa
Regina Osih Clinton Health Access Initiative South Africa
Andreas Diacon University of Stellenbosch South Africa
Valerie Mizrahi UCT-Institute of Infectious Disease and Molecular Medicine South Africa
Gill Black Sustainable Livelihoods Foundation South Africa
Dalene von Delft TB Proof South Africa
Chris Edlin iThemba Pharmaceuticals South Africa
Hulda Swai Council of Scientific Industrial Research (CSIR) in South Africa South Africa
Wim Vandevelde European AIDS Treatment Group (EATG); Community Representative South Africa
Victoria Kasprowicz SANTHE South Africa
Boitumelo Semete Council of Scientific Industrial Research (CSIR) in South Africa South Africa
Christo van Niekerk TB Alliance South Africa
Gerhard Walzl Stellenbosch University South Africa
Parameshwar Makam University of KwaZulu-Natal South Africa
Kristina Wallengren THINK South Africa
Bavesh Kana University of the Witwatersrand/National Health Laboratory Service South Africa
Anneke Hesseling Desmond Tutu TB Centre South Africa
Jonathan Blackburn University of Cape Town South Africa
Robert Wallis Aurum Institute South Africa
Sang Jae Kim Korean Institute of Tuberculosis South Korea
Sang Nae Cho Yonsei University College of Medicine South Korea
Kevin Pethe Institut Pasteur-Korea South Korea
Robert Bates GlaxoSmithKline Spain
Joan A. Cayla Agència de Salut Pública de Barcelona Spain
Pere-Joan Cardona Institut Germans Trias i Pujol (IGTP) Spain
Lluís Ballell GlaxoSmithKline Tres Cantos Spain
David Barros GlaxoSithKline Spain
Santiago Ramón García Research Agency of Aragon (ARAID) Spain
Asaad Khalid Ahmed National Center for Research Sudan
Stephen Matlin Global Forum for Health Research Switzerland
Mario Raviglione World Health Organization (WHO) Switzerland
Marc Gitzinger BioVersys AG Switzerland
Rick O'Brien Foundation for Innovative New Diagnostics Switzerland
Neeraj Dhar École Polytechnique Fédérale de Lausanne (EPFL) Switzerland
Malgosia Grzemska World Health Organization (WHO) Switzerland
Stewart Cole École Polytechnique Fédérale de Lausanne (EPFL) Switzerland
Iain Old Innovative Medicines for TB (iM4TB) Switzerland
Klaus Reither Swiss Tropical and Public Health Institute Tanzania
Prasit Palittapongarnpim Mahidol University Thailand
Sonja Henne MSF Tunisia
Joshua Wamboga Uganda Network of AIDS Service Organisations (UNASO) Uganda
Yap Boum II Epicentre/MSF Uganda
Galyna Kutsyna Luhansk State Medical University Ukraine
Andriy Dudnyk National Medical University of Vinnytsia, Ukraine Ukraine
Juan David Guzman Birkbeck College United Kingdom
Brian Robertson Imperial College London United Kingdom
Amina Jindani St. George's, University of London United Kingdom
Roger Moses iThemba Pharmaceuticals United Kingdom
Ibrahim Abubakar University College London, MRC Clinical Trials Unit United Kingdom
Polly Clayden HIV i-Base United Kingdom
Richard White London School of Hygiene and Tropical Medicine United Kingdom
Dennis Mitchison St Georges. University of London United Kingdom
Sanjib Bhakta The Institute of Structural and Molecular Biology, Birkbeck, University of London United Kingdom
Oscar Della Pasqua GlaxoSmithKline United Kingdom
Simon Tiberi Barts Healthcare NHS Trust United Kingdom
Arun Kumar Mishra University of Birmingham United Kingdom
Mary Jackson Colorado State University United States
Payam Nahid University of California, San Francisco United States
Carl Nathan Weill Cornell Medical College United States
Shichun Lun Johns Hopkins University School of Medicine United States
Jim Boyce National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Christine Sizemore National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Diane Ordway Colorado State University United States
Gary Horwith BARDA United States
James Frincke Hollis Eden Pharmaceuticals United States
Leo Einck Sequella, Inc. United States
Tiansheng Wang Vertex Pharmaceuticals United States
Chris Dippel Peloton Partnering, SP United States
Oleg Tsodikov University of Kentucky United States
Anthony Baughn University of Minnesota United States
Sylvie Garneau-Tsodikova University of Michigan United States
Gilla Kaplan Bill & Melinda Gates Foundation United States
Anna Upton TB Alliance United States
Carole Mitnick Harvard Medical School United States
David Sherman University of Washington United States
Eric Nuermberger Johns Hopkins University United States
Ian Orme Colorado State University United States
Kenneth Castro Emory University United States
Tawanda Gumbo University of Texas Southwestern Medical Center at Dallas United States
Omar Vandal Bill and Melinda Gates Foundation United States
Barry Bunin Collaborative Drug Discovery United States
Helena Boshoff National Institutes of Health (NIH) United States
Kyu Rhee Weill Cornell Medical College United States
Petros Karakousis Johns Hopkins University School of Medicine United States
Rajneesh Taneja TB Alliance United States
John Szumowski Santa Clara Valley Medical Center United States
Cathy Bansbach Bill & Melinda Gates Foundation United States
Bonita Mangura Global TB Institute at UMDNJ United States
Christopher Sassetti University of Massachusetts Medical School United States
Dirk Schnappinger Weill Cornell Medical College United States
Gyanu Lamichhane Johns Hopkins University United States
Jan Gheuens Bill & Melinda Gates Foundation United States
Mamodikoe Makhene National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Michael Cynamon VAMC, SUNY, Upstate Medical University United States
Ute Muh University of Iowa United States
Maggie McCammon Michigan Economic Development Corporation United States
Heinz Moser Achaogen United States
Debra Hanna CPTR, Critical Path Institute United States
Brian VanderVen Cornell University United States
Allen Casey Infectious Disease Research Institute (IDRI) United States
Barbara Laughon National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Gail Cassell Research America United States
Lawrence Geiter Otsuka Pharmaceutical Company United States
Mary Ann de Groote Colorado State University United States
Jing Bao National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Joel Freundlich UMDNJ - New Jersey Medical School United States
Frances Pappas TB Alliance United States
Mark Harrington Treatment Action Group United States
David Russell Cornell University United States
Jeffery Cirillo Texas A&M Health Science Center United States
Shashi Kant UT Southwestern Medical Center United States
Liyanage Perera National Institutes of Health (NIH) United States
Francisco Leyva National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Ann Ginsberg Aeras United States
Carol Nacy Sequella, Inc. United States
Claire Wingfield PATH United States
Ken Duncan Bill & Melinda Gates Foundation United States
Marina Protopopova National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Robert Husson Children's Hospital Boston/Harvard Medical School United States
Edward Nardell Partners in Health United States
Khisimuzi Mdluli TB Alliance United States
Clifton Barry National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Ying Zhang Johns Hopkins University United States
Erica Lessem Treatment Action Group United States
Bolin Geng Ra Pharma United States
Amy Bloom United States Agency for International Development (USAID) United States
James Love Knowledge Ecology International (KEI) United States
Melvin Spigelman TB Alliance United States
Richard Chaisson Johns Hopkins University Center for TB Research United States
Todd Waldman Easton Associates United States
Gail Tauscher National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Cherise Scott TB Alliance United States
Christopher Cooper Global Alliance for TB Drug Development (TB Alliance) United States
Matthew Price Harvard School of Public Health United States
Michaela Nielsen Regulatory Affairs Consultant United States
C. Robert Horsburgh Boston University School of Public Health United States
Edward Berry SUNY Upstate Medical University United States
Peter Warner Bill and Melinda Gates Foundation United States
Anne Lenaerts Colorado State University United States
Charles Wells Sanofi United States
David McNeeley Medical Service Corportation International (MSCI) United States
Martin Springsklee Bayer Healthcare United States
Scott Franzblau Institute for Tuberculosis Research, University of Illinois at Chicago United States
Tanya Parish Infectious Disease Research Institute (IDRI) United States
Philip Hipskind Eli Lilly and Company; Lilly Research Laboratories United States
Sharon Williams National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Barry Furr Astrazeneca United States
Martin Graham KinderPharm United States
Shashank Gupta Brown University United States
Laura Via National Institute for Allergy and Infectious Diseases (NIH/NIAID) United States
Andrew Vernon U.S. Centers for Disease Control and Prevention (CDC) United States
Carol Dukes Hamilton Family Health International United States
Christopher Locher Baxalta United States
Doris Rouse RTI International United States
Maria Freire Lasker Foundation United States
Takushi Kaneko TB Alliance United States
William Bishai Johns Hopkins School of Medicine United States
William Chamberlin Texas Tech University Health Sciences Center United States
Jerome Zeldis Celgene United States
Bob Goldman RCG Consulting United States
Philip Onyebujoh WHO Regional Office for Africa Zimbabwe
Albert Makone Community Representative; Global Fund (local) Zimbabwe

New Members


The Working Group pipeline is open to anyone who is developing a TB drug. If you would like to become a member, please submit an application.

Apply Now

Questions? Contact Us